#ctDNA
LightNews LightNews
barbmarte.bsky.social
new out in @nature www.nature.com/articles/s41...
ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2 - Nature
Nature - ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2
www.nature.com
October 29, 2026 at 8:36 AM
onclive.bsky.social
👀 @elmayermd.bsky.social, of @danafarber.bsky.social and @harvardmed.bsky.social, discusses the @fda.gov approval of camizestrant for ESR1-mutated HR+/HER2– breast cancer and the importance of ctDNA monitoring. #bcsm #oncology

Read more ➡️: www.onclive.com/view/camizes...
Camizestrant Approval Paves the Way for ctDNA-Guided Switching in Emergent ESR1-Mutated HR+/HER2– Advanced Breast Cancer | OncLive
Erica L. Mayer, MD, MPH, discusses the FDA approval of camizestrant for ESR1-mutated HR+/HER2– breast cancer and the importance of ctDNA monitoring.
www.onclive.com
November 2, 2026 at 10:39 PM
biorxivpreprint.bsky.social
Coupled Modeling of Tumor Volume and ctDNA Dynamics in HPV-Associated Anal Squamous Cell Carcinoma https://www.biorxiv.org/content/10.64898/2026.11.01.763528v1
November 3, 2026 at 3:47 PM
biorxiv-cancer.bsky.social
Coupled Modeling of Tumor Volume and ctDNA Dynamics in HPV-Associated Anal Squamous Cell Carcinoma https://www.biorxiv.org/content/10.64898/2026.11.01.763528v1
November 3, 2026 at 3:47 PM
targetedonc.bsky.social
Do we need a baseline ctDNA draw to tell if immunotherapy is working in NSCLC? Valsamo “Elsa” Anagnostou, MD, PhD,
@hopkinsmedicine.bsky.social, says one sample 3 to 9 weeks in may be enough. New on Targeted Talks 🔈: targetedonc.com/view/beyond-...
Beyond the Scan: Predicting Immunotherapy Response With ctDNA in NSCLC | Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways
Hear how a single ctDNA blood draw 3 to 9 weeks into immunotherapy may reveal response earlier than imaging in NSCLC, with Valsamo Anagnostou, MD, PhD.
www.targetedonc.com
November 3, 2026 at 1:22 PM
icthealth.nl
Who really benefits from chemotherapy after colorectal cancer surgery? DoMore Diagnostics’ AI biomarker analyses existing tumour slides. In 900+ ctDNA-negative patients, Histotype Px identified around two-thirds of recurrences missed by ctDNA testing. #healthcare
AI biomarker could improve colorectal cancer treatment | ICT&health
An AI-based biomarker could help oncologists determine which colorectal cancer patients are likely to benefit from chemotherapy after surgery.
www.icthealth.org
November 3, 2026 at 4:03 PM
jmdiagn.bsky.social
New month, new #LegacyContent! The full November 2025 issue is now free in the #OpenArchive.

Full issue: https://www.jmdjournal.org/issue/S1525-1578(24)X0013-6

#ctDNA #adenovirus #chromosomalvariant
November 2, 2026 at 2:11 PM
eshg.bsky.social
📄 New paper in Nature: “ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2”

🔬 Combined assessment of ctDNA clearance and pathological complete response status may improve risk stratification in NSCLC

🔗 doi.org/10.1038/s415...
October 30, 2026 at 6:00 AM
natmed.nature.com
A 5-year analysis of the phase 2 PHERGain trial supports the clinical utility of a PET-guided adaptive strategy for treatment de-escalation in HER2+ early breast cancer, and provides ctDNA insights to inform treatment de-escalation approaches
5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial - Nature Medicine
A 5-year secondary analysis of the phase 2 PHERGain trial supports the clinical utility of a PET-guided adaptive strategy for treatment de-escalation in HER2-positive early breast cancer and provides circulating tumor DNA insights that could inform further treatment approaches.
dlvr.it
November 2, 2026 at 11:40 AM
edufabtech.com
ctDNA Clearance Before Surgery Tracks Outcomes in Phase 2 NeoCOAST-2 Lung Cancer Trial

#ClinicalTrial #LiquidBiopsy #LungCancer #Oncology

edufabtech.com/news/ctdna-c...
October 28, 2026 at 7:49 AM
edufabtech.com
ctDNA Clearance Before Surgery Tracks Outcomes in Phase 2 NeoCOAST-2 Lung Cancer Trial

#ClinicalTrial #LiquidBiopsy #LungCancer #Oncology

edufabtech.com/news/ctdna-c...
October 28, 2026 at 7:49 AM
myesmo.bsky.social
#ESMO26: Detection of #ctDNA fractions with a single tumour-informed and tumour-agnostic profiling assay strongly predicted relapse and overall survival in a #LungCancer cohort from the #TRACERx programme

🔗 https://ow.ly/1wGS5100nzk

#InsightsbyESMO #NSCLC #LiquidBiopsy
October 27, 2026 at 2:30 PM
drtimos.bsky.social
🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TW5dSG
@ASCO

#SocialListening #LucidQuest
ASCO GI 2025 SoMe Report.pdf
dlvr.it
October 28, 2026 at 7:06 PM
susangkomen.bsky.social
What if a few cancer cells remain after breast cancer treatment, even when scans show no signs of disease? Learn how MRD differs from what imaging can detect and how ctDNA may reveal molecular evidence of residual disease. Full episode: https://bit.ly/4zfpPAL
October 28, 2026 at 4:29 PM
ampath.bsky.social
TODAY: Join us at 1 p.m. Eastern for a free webinar on the principles, technologies and clinical applications of ctDNA-based MRD detection.

Register: https://educate.amp.org/local/catalog/view/product.php?productid=614
October 29, 2026 at 1:00 PM
drtimos.bsky.social
🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TW5dSG
@ASCO

#SocialListening #LucidQuest
ASCO GI 2025 SoMe Report.pdf
dlvr.it
October 28, 2026 at 7:06 PM
meducationai.bsky.social
A good case for reading a non-inferiority trial: start with the margin, then the population. For responders on immunotherapy the open question is less whether to de-escalate and more who, and that's where response depth and ctDNA could help.
October 28, 2026 at 7:32 PM
meducationai.bsky.social
Combining tumour-informed and tumour-agnostic profiling in one assay is a smart step. The teaching point we stress: a negative postoperative ctDNA lowers risk but isn't proof of cure, because low-shedding tumours like many lung adenocarcinomas can still relapse.
October 27, 2026 at 11:59 PM
vcclibrary.bsky.social
Talazoparib plus enzalutamide versus placebo plus enzalutamide in metastatic androgen pathway modulator-resistant (castration-resistant) prostate cancer (TALAPRO-2): a biomarker analysis of circulating tumour DNA and cells for prognosis and molecular profiling www.thelancet.com/journals/lan...
Talazoparib plus enzalutamide versus placebo plus enzalutamide in metastatic androgen pathway modulator-resistant (castration-resistant) prostate cancer (TALAPRO-2): a biomarker analysis of circulatin...
Our results support broad prognostic utility of ctDNA burden and CTC enumeration in metastatic APMR prostate cancer, including in the context of poly(ADP) ribose polymerase inhibitor therapy.
www.thelancet.com
October 30, 2026 at 10:56 AM
southamptonctu.bsky.social
Our SCTU team has been at #ESMO26 over the past few days showcasing some of our #ClinicalTrials, including our SAFE-D and iDx Lung #EarlyDiagnosis studies, and DETECTION-2 which aims to use ctDNA testing to indicate the return of #melanoma after surgery.

#CancerResearch #EarlyDetection #cancer
October 26, 2026 at 4:17 PM
jclub.com.au
Which add-on drug best cleared tumour DNA from the blood in resectable lung cancer?

Worth a read from Nature: In resectable stage IIA–IIIB NSCLC in NeoCOAST-2, ctDNA clearance at neoadjuvant Cycle 3 Day 1 was highest with Dato-DXd (72.5%).

#LungCancer

doi.org/10.1038/s41586-026-11328-3
ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2.
Nature · 1 post on Bluesky this week.
jclub.com.au
October 27, 2026 at 5:39 AM
tiansterzhangmd.bsky.social
Interesting ctDNA analysis from #EV304/B15 trial — ctDNA (+) groups w poor prognosis but EV-pembro works regardless of ctDNA status
@myESMO #ESMO26 @oncoalert
October 23, 2026 at 12:46 PM
chucky.bsky.social
ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2
ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2
chuckyscarnage.tech.blog
October 25, 2026 at 9:41 AM
genomeweb.bsky.social
Researchers found that ctDNA analysis can provide indication of early progression for Lorbrena, while the biomarker did not show to be clearly useful for selecting patients for Tagrisso.
Experts at ESMO Unsure if ctDNA Should Alter Intensification Strategy With NSCLC Targeted Therapy
Experts at ESMO Unsure if ctDNA Should Alter Intensification Strategy With NSCLC Targeted Therapy
ebx.sh
October 25, 2026 at 4:33 PM
oncologyeducation.bsky.social
Carlos Barcenas, MD, MSc, on pre-interim results from B-STRONGER-I: ultrasensitive ctDNA monitoring during neoadjuvant treatment in early-stage triple-negative breast cancer. #ESMO26

Watch now: https://bit.ly/4Bk5ag6
October 26, 2026 at 5:35 PM